Oral Session 1-14A ALL: Basic (1)

[OS1-14A-1] The between MTX clearance and genetic variants in high-dose MTX therapy for ALL

Yoichi Tanaka¹, Kevin Urayama², Makiko Mori³, Daisuke Hasegawa⁴, Koshi Akahane⁵, Setsuo Ota⁶, Katsuyoshi Koh³, Atsushi Manabe⁴ (1.Clinical Pharmacy, School of Pharmacy, Kitasato University, Tokyo, Japan, 2.National Center for Child Health and Development, Tokyo, Japan, 3.Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama, Japan, 4.Department of Pediatrics, St. Luke's International Hospital, Tokyo, Japan, 5.Department of Pediatrics, University of Yamanashi, Yamanashi, Japan, 6.Department of Pediatrics, Teikyo University Chiba Medical Center, Chiba, Japan)